As current treatments for ADHD do not appear to change the likelihood of ND in these patients, understanding the role of D1‐R/NMDA‐R mediated ERK signaling in these patients may open new avenues for future treatment. This evidence concerns the gene MAPK1 and attention deficit-hyperactivity disorder.